Connect with us
Prague Gaming & TECH Summit 2024

Fintech PR

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Published

on

chronic-rhinosinusitis-with-nasal-polyps-market-to-witness-upsurge-in-growth-at-a-cagr-of-10.03%-during-the-study-period-(2019-2032),-examines-delveinsight

The overall chronic rhinosinusitis with nasal polyps market is expected to grow due to the increase in the diagnosed prevalent population of CRSwNP across the globe and thus the surge in demand for treatment. The expected launch of emerging therapies will further boost the CRSwNP treatment market in the forecasted period (2023–2032).

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ — DelveInsight’s Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Chronic Rhinosinusitis with Nasal Polyps Market Report

  • As per DelveInsight analysis, the total CRSwNP market size in the 7MM was approximately USD 1.8 million in 2022 and is projected to increase during the forecast period (2023–2032).
  • As per DelveInsight estimates, there were 4.3 million diagnosed prevalent cases of CRSwNP estimated to have occurred in the 7MM in 2022.
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.

Discover which therapies are expected to grab the major chronic rhinosinusitis with nasal polyps market share @ Chronic Rhinosinusitis with Nasal Polyps Market Report

Chronic Rhinosinusitis with Nasal Polyps Overview

Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks. Patients suffering from CRS can develop CRS with nasal polyposis (CRSwNP) and CRS without nasal polyposis (CRSsNP). CRSwNP is thus a subset of CRS, with roughly one-fourth of CRS patients developing the disease. Chronic sinus infections, allergic rhinitis, asthma, cystic fibrosis, susceptibility to NSAIDs like ibuprofen and aspirin, and Churg-Strauss syndrome are all risk factors for CRSwNP. Chronic nasal congestion, running nose, postnasal drip, decreased sense of smell and taste, trouble breathing, pressure in the face or forehead area, snoring, sleep apnea, anterior or posterior rhinorrhea, and other symptoms may occur. An ENT expert or another physician examines the nasal passages with a special illuminated equipment known as a nasoscope to make the initial diagnosis of CRSwNP. Nasal endoscopy and radiological imaging are the most commonly used procedures for validating the location, size, and severity of polyps. 

Chronic Rhinosinusitis with Nasal Polyps Epidemiology Segmentation

The diagnosed prevalent cases of CRSwNP were further divided into Gender-specific cases. The Gender-specific diagnosed prevalent cases of CRSwNP are categorized into males and females with 1.2 million and 986K cases respectively in the US in 2022, which is expected to further increase in 2032.

The chronic rhinosinusitis with nasal polyps market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Prevalent Cases of Chronic Rhinosinusitis
  • Diagnosed Prevalent Cases of Chronic Rhinosinusitis
  • Diagnosed Prevalent Cases of CRSwNP
  • Gender-specific Diagnosed Prevalent Cases of CRSwNP

Chronic Rhinosinusitis with Nasal Polyps Treatment Market 

Depending on the specific instance, the typical treatment for CRSwNP includes a combination of pharmacological and surgical treatments. Patients are generally treated medically in primary care settings before considering surgical options. Treatment attempts to eradicate or greatly reduce the size of the CRSwNP, resulting in nasal obstruction reduction, sinus drainage improvement, and olfaction and taste restoration. Any associated rhinitis symptoms may also necessitate treatment. Recurrences are prevalent with both therapies, especially in asthma sufferers, who are twice as likely as nonasthmatics to develop recurrence.

CRSwNP is currently treated with corticosteroids (both intranasal and systemic), as well as antihistamines, antibiotics, and NSAIDs, which are provided based on the patient’s needs. Endoscopic surgery is indicated to remove polyps and fix problems with your sinuses that make them prone to inflammation and the growth of polyps when medication treatment does not shrink or eliminate nasal polyposis. In addition to biologics, corticosteroid nasal spray is indicated after surgery to avoid the recurrence of nasal polyposis. XHANCE (fluticasone propionate), SINUVA (mometasone furoate) Sinus Implant, PROPEL (mometasone furoate), DUPIXENT (dupilumab), XOLAIR (omalizumab), and NUCALA (mepolizumab) have all been authorized by the US FDA for the treatment of CRSwNP.

Intranasal glucocorticoids (budesonide, fluticasone, and mometasone) may improve rhinorrhea, reduce polyp growth, and partially or completely restore the sense of smell. According to experts, physicians tend to under-administer intranasal glucocorticoids and prescribe them at levels that are ineffective. Patients also tend to take these products seldom when they are prescribed.

To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management 

Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapies and Key Companies

  • FASENRA (benralizumab): AstraZeneca
  • TEZSPIRE (tezepelumab): AstraZeneca/Amgen
  • Depemokimab/GSK3511294: GlaxoSmithKline
  • CM310: Keymed Biosciences
  • NURTEC (rimegepant): Biohaven Pharmaceuticals

Learn more about the FDA-approved drugs for chronic rhinosinusitis with nasal polyps @ Drugs for Chronic Rhinosinusitis with Nasal Polyps Treatment 

Chronic Rhinosinusitis with Nasal Polyps Market Dynamics

The dynamics of the chronic rhinosinusitis with nasal polyps are expected to change in the coming years. The disease’s increasing prevalence is likely to result in an increase in treatment choices, and as a result, the market may see an increase in the coming years. The recent entrance of NUCALA and XOLAIR into the CRSwNP market has provided additional biologic choices to choose from. Because almost half of CRSwNP patients do not know the reason of their symptoms, proactive initiatives to target this patient demographic could boost the entire CRSwNP market. There are prospects for cost-effective treatment solutions for people with severe recurrent CRSwNP.

Furthermore, many potential therapies are being investigated for the treatment of CRSwNP, and it is safe to predict that the treatment space will significantly impact the CRSwNP market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the CRSwNP market in the 7MM.

However several factors may impede the growth of the CRSwNP market. Current medicines, such as corticosteroids, are not differentiated based on the severity of the condition, but rather are used in all patients. A significant proportion of CRSwNP patients remain undiagnosed, which may impede CRSwNP market expansion. Another major cause of bad present patient care is a lack of disease knowledge among doctors, which may impede CRSwNP market expansion. In addition, the availability of less expensive off-label medications on the CRSwNP market, might provide a hurdle to new therapies.

Moreover, CRSwNP treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the CRSwNP market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the CRSwNP market growth.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Chronic Rhinosinusitis with Nasal Polyps Market CAGR

10.03 %

Chronic Rhinosinusitis with Nasal Polyps Market Size in 2022

USD 1.8 Billion

Key Chronic Rhinosinusitis with Nasal Polyps Companies

AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others

Key Pipeline Chronic Rhinosinusitis with Nasal Polyps Therapies

FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others

Scope of the Chronic Rhinosinusitis with Nasal Polyps Market Report

  • Therapeutic Assessment: Chronic Rhinosinusitis with Nasal Polyps current marketed and emerging therapies
  • Chronic Rhinosinusitis with Nasal Polyps Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Rhinosinusitis with Nasal Polyps Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Chronic Rhinosinusitis with Nasal Polyps Market Access and Reimbursement

Discover more about chronic rhinosinusitis with nasal polyps drugs in development @ Chronic Rhinosinusitis with Nasal Polyps Clinical Trials

Table of Contents

1.

Chronic Rhinosinusitis with Nasal Polyps Key Insights

2.

Chronic Rhinosinusitis with Nasal Polyps Report Introduction

3.

Chronic Rhinosinusitis with Nasal Polyps Overview at a Glance

4.

Chronic Rhinosinusitis with Nasal Polyps Executive Summary

5

Chronic Rhinosinusitis with Nasal Polyps Key Events

6

Epidemiology and Market Forecast Methodology

6.

Disease Background and Overview

7.

Chronic Rhinosinusitis with Nasal Polyps Treatment and Management

8.

Chronic Rhinosinusitis with Nasal Polyps Guidelines

9.

Chronic Rhinosinusitis with Nasal Polyps Epidemiology and Patient Population

10.

Patient Journey

11.

Key Endpoints in Chronic Rhinosinusitis with Nasal Polyps 

12.

Chronic Rhinosinusitis with Nasal Polyps Marketed Drugs

13.

Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs

14.

7MM Chronic Rhinosinusitis with Nasal Polyps Market Analysis

15.

Market Access and Reimbursement

16.

KOL Views

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Related Reports

Chronic Rhinosinusitis with Nasal Polyps Epidemiology Forecast

Chronic Rhinosinusitis with Nasal Polyps Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and chronic rhinosinusitis with nasal polyps epidemiology trends.

Chronic Rhinosinusitis with Nasal Polyps Pipeline

Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic rhinosinusitis with nasal polyps companies, including Keymed Biosciences, Connect Biopharma, AstraZeneca, Amgen, Pfizer, Trellis Bioscience LLC, GlaxoSmithKline, Gossamer Bio Inc., Biohaven Pharmaceuticals, Inc., Insmed Incorporated, Lyra Therapeutics, among others.

Chronic Rhinosinusitis without Nasal Polyps Market

Chronic Rhinosinusitis without Nasal Polyps Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic rhinosinusitis without nasal polyps companies including AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, among others.

Chronic Rhinosinusitis without Nasal Polyps Epidemiology

Chronic Rhinosinusitis with Nasal Polyps Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and chronic rhinosinusitis without nasal polyps epidemiology trends.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com

Logo – https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/chronic-rhinosinusitis-with-nasal-polyps-market-to-witness-upsurge-in-growth-at-a-cagr-of-10-03-during-the-study-period-20192032-examines-delveinsight-302009239.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Velo Is Enhancing Its Own Ecosystem Through Interoperability

Published

on

velo-is-enhancing-its-own-ecosystem-through-interoperability

Interoperability in Velo: To Infinity and Beyond

BANGKOK, March 5, 2024 /PRNewswire/ — As new blockchains and blockchain-based platforms emerge, it’s crucial for these ecosystems to be interconnected, enabling users to seamlessly transfer their assets without complications. Velo is enhancing its own ecosystem through interoperability, aspiring to become a pivotal connection point for various blockchains.

A significant update within Universe is its support for multiple wallet addresses on a single platform, catering to users who possess multiple wallets across different platforms. This feature is essential for managing diverse assets conveniently.

Furthermore, Universe is integrating multi-chain login and registration support for networks such as Solana and Tron, thereby improving Velo’s accessibility and usability. Efforts are in place to refactor the user database and management code, ensuring a smooth and secure experience.

Velo is advancing its blockchain integration by incorporating the Solana and Tron networks, aiming to offer enhanced deposit and withdrawal functionalities to enrich its ecosystem. This initiative involves deploying Solana and Tron chain-node and full-node functionalities, thereby broadening the network’s diversity and user options. Additionally, Universe is introducing a dedicated user interface (UI) for Solana transactions, encompassing deposit-withdrawal and account management across Webplus and mobile platforms, ensuring a seamless user experience.

This streamlined approach guarantees that Velo’s users have comprehensive and intuitive access to a broader range of transaction options, significantly boosting the platform’s utility and user engagement.

The integration with the Lightning Network marks a significant advancement in improving Bitcoin transactions. By implementing Lightning chain-node and deploying a BTC full-node, Orbit aims to streamline Bitcoin deposits and withdrawals, making them faster and more cost-efficient.

Velo’s dedication to ensuring inclusivity and connectivity with other blockchains is evident through the concrete steps it has taken. With aggressive strides towards unlocking the full potential of the Velo Protocol, Velo is poised for significant growth and innovation.

About Velo Labs

Velo Labs is a global pioneer in Web3-based financial solutions, offering a cutting-edge liquidity and settlement network for secure, efficient value transfers. Backed by Stellar Network and CP Group, our reach has expanded beyond Southeast Asia and the Pacific, now serving partners worldwide. We connect and complement the gap between traditional banking infrastructure and Web3, leading the way in blockchain mass adoption. Our extensive Web3-based payment network and Lightnet, our licensed settlement partner, position us as a global heavyweight. Velo Labs offers a diverse range of Web3-based products, notably Orbit, tailored for individuals, merchants, corporations, and enterprises worldwide — dedicated to empowering global financial connectivity and expanding accessibility globally.

Follow us for more info: Twitter / Telegram / Website

View original content:https://www.prnewswire.co.uk/news-releases/velo-is-enhancing-its-own-ecosystem-through-interoperability-302079542.html

Continue Reading

Fintech PR

CGTN: China vows to develop new quality productive forces in modernization drive

Published

on

cgtn:-china-vows-to-develop-new-quality-productive-forces-in-modernization-drive

BEIJING, March 5, 2024 /PRNewswire/ — China saw the number of contracted technology transactions grow by 28.6 percent in 2023, an achievement that speaks volumes of the country’s enhanced capacity for innovation-driven development.

China will leverage the leading role of innovation, spur industrial innovation through advancements in science and technology, and press ahead with new industrialization, according to a government work report submitted on Tuesday to the national legislature for deliberation.

Chinese Premier Li Qiang delivered the report at the opening meeting of the second session of the 14th National People’s Congress in the Great Hall of the People in Beijing.

The report says that the country will strive to modernize the industrial system and develop new quality productive forces at a faster pace.

Developing new quality productive forces

With innovation leading the way, new quality productive forces mean going beyond the traditional models of economic growth. This path features high technology, high efficiency and high quality, and aligns with China’s new development philosophy.

In order to develop these new quality productive forces, the government work report lists a series of tasks.

It calls for improving and upgrading industrial and supply chains besides cultivating emerging and future-oriented industries, such as hydrogen power, new materials, biomanufacturing, commercial spaceflight, quantum technology and life sciences.

The report also says that innovative development of the digital economy will be promoted, an Artificial Intelligence Plus initiative will be launched, and the country will consolidate and enhance its leading position in industries such as intelligent connected new-energy vehicles.

Moreover, China has set an economic growth target of around 5 percent for 2024 and vowed to promote high-quality development. It will issue ultra-long special treasury bonds annually over the next several years for implementing major national strategies and building up security capacity in key areas, starting with 1 trillion yuan of such bonds this year, according to the report.

The report also stresses efforts for invigorating China through science and education and consolidating the foundations for high-quality development.

China will speed up efforts to build a contingent of personnel with expertise of strategic importance and cultivate more first-class scientists and innovation teams.

The country will develop platforms for identifying basic research talent, train high-performing engineers and highly-skilled workers, and enhance support for young scientists and engineers, according to the report.

Acting on people-centered development philosophy

China will make efforts to ensure and improve the people’s welling and promote better and new ways of conducting social governance, the report says.

It highlights that China will deliver real benefits to the people to their satisfaction by acting on the people-centered development philosophy.

In 2023, China’s per capita disposable income of residents increased by 6.1 percent, and over 66 million taxpayers benefited from an increase in the special additional deductions for individual income tax, which cover children nursing expenses, children’s education and elderly care expenses, according to the report.

In 2024, the country expects to create over 12 million jobs in urban areas and keep the surveyed urban unemployment rate at around 5.5 percent.

China will also enhance ecological conservation and promote green and low-carbon development, including taking comprehensive steps to improve the environment and boosting the green and low-carbon economy, according to the report.

In 2023, China’s installed renewable energy capacity surpassed its thermal power capacity for the first time in history and it accounted for over half of newly installed renewable energy capacity worldwide, according to data released by the National Energy Administration.

The country will advance the energy revolution and actively and prudently work toward peaking carbon dioxide emissions and achieving carbon neutrality, according to the report.

https://news.cgtn.com/news/2024-03-05/China-s-top-legislature-starts-annual-session-1rImSPDg5EI/p.html

View original content:https://www.prnewswire.co.uk/news-releases/cgtn-china-vows-to-develop-new-quality-productive-forces-in-modernization-drive-302079529.html

Continue Reading

Fintech PR

SK chemicals, Hyosung Advanced Materials, and Hankook Tire Commercialize South Korea’s First Chemically Recycled PET Tire

Published

on

sk-chemicals,-hyosung-advanced-materials,-and-hankook-tire-commercialize-south-korea’s-first-chemically-recycled-pet-tire
  • Establishing a circular economy that extends from recycled PET to high-strength tire cords and electric vehicle-exclusive tires
  • Leading the global tire industry’s sustainable management by commercializing products with 45% eco-friendly certified materials

SEONGNAM, South Korea, March 5, 2024 /PRNewswire/ — To reduce carbon emissions, the South Korean industrial sector has developed and commercialized the country’s first tire using chemically recycled PET.

SK chemicals (CEO Ahn Jae-hyun), Hyosung Advanced Materials Co., Ltd. (CEO Cho Yong-soo), and Hankook Tire & Technology Co., Ltd. (CEO Lee Soo-il, hereafter Hankook Tire) announced on the 5th that they have successfully developed the electric vehicle-exclusive tire “iON” applying “circular recycled PET (polyester) fiber tire cords.” Circular recycling is an exclusive chemical recycling technology of SK chemicals that breaks down discarded plastics through chemical reactions into molecular units and then uses these raw materials to produce recycled plastics.

Before the commercialization phase, there were instances where chemical recycling technology was applied to concept tires or prototypes, but the release of a tire product to the market using chemically recycled PET-based tire cords through to commercialization is a first in South Korea.

SK chemicals, Hyosung Advanced Materials, and Hankook Tire have collaboratively developed this tire over a period of about two years. SK chemicals has reliably supplied the circular recycled PET “SKYPET CR”, and Hyosung Advanced Materials developed the high-strength recycled PET-based tire cords using this as a raw material. The developed tire cords were applied to Hankook Tire’s premium electric vehicle tire brand, iON. The iON tire, with a 45% sustainable material content, has recently passed the stringent reliability verification by a European automotive manufacturer, securing final approval for use and being mounted as tires for new vehicles.

Tire cords are fiber reinforcement materials that help maintain the shape of the tire and withstand the load and impact applied during driving, enhancing the tire’s durability, driving performance, and ride comfort.

SK chemicals’ “SKYPET CR” has the advantage of maintaining high-quality properties and safety even after infinite recycling, compared to the physical recycling method of washing discarded plastics or cutting them into flakes for reuse, and it can achieve properties equivalent to petrochemical-based materials.

The iON model developed by Hankook Tire incorporates 45% sustainable materials, including bio-based, circular, and bio-circular polymers, bio-based silica along with Hyosung Advanced Materials’ tire cords, and the model is the first tire to bear the ISCC PLUS certification logo.

 

SK Chemicals Logo

Photo – https://mma.prnewswire.com/media/2353435/Sustainable_tires_commercialized_SK_chemicals_Hyosung_Advanced_Materials_Hankook_Tire.jpg
Logo – https://mma.prnewswire.com/media/2030193/SK_Chemicals_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/sk-chemicals-hyosung-advanced-materials-and-hankook-tire-commercialize-south-koreas-first-chemically-recycled-pet-tire-302078307.html

Continue Reading

Trending